Back to Search
Start Over
[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus].
- Source :
-
Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion [Endocrinol Nutr] 2011 Aug-Sep; Vol. 58 (7), pp. 331-40. Date of Electronic Publication: 2011 Jun 29. - Publication Year :
- 2011
-
Abstract
- Background and Objectives: Exenatide, a GLP-1 receptor agonist for adjuvant treatment of type 2 diabetes mellitus (T2DM), has been shown to be as effective as insulin glargine (IG) for reducing glycated hemoglobin levels combined with metformin or/and sulphonylureas. Exenatide is associated to weight reduction and a higher incidence of gastrointestinal adverse events. The objective of this study was to assess the cost-effectiveness of exenatide as compared to IG in obese patients with T2DM not achieving an adequate blood glucose control from the perspective of the Spanish healthcare system.<br />Methods: Pharmacoeconomic model inputs were obtained from an obese subpopulation (BMI ≥ 30 k/m(2)) of an international, randomized, controlled clinical trial comparing exenatide with IG in poorly controlled T2DM patients, and were supplemented with country-specific data.<br />Results: Exenatide was associated to improvements in life-years gained and quality-adjusted life years (QALYs) by 0.11 and 0.62 respectively versus IG. Direct costs were € 9,306 higher as compared to IG (€ 47,010 versus € 37,704, with increased pharmacy costs as the main driver). Exenatideís incremental cost-effectiveness ratio was € 15,068 per QALY gained versus IG.<br />Conclusions: Exenatide was associated to greater clinical benefits and higher costs in obese T2DM patients as compared to IG. Considering a willingness-to-pay threshold of € 30,000 per QALY gained in the Spanish setting, exenatide represents an efficient option in comparison with IG.<br /> (Copyright © 2010 SEEN. Published by Elsevier Espana. All rights reserved.)
- Subjects :
- Cost-Benefit Analysis
Exenatide
Female
Humans
Insulin Glargine
Male
Middle Aged
Diabetes Mellitus, Type 2 complications
Hypoglycemic Agents economics
Hypoglycemic Agents therapeutic use
Insulin, Long-Acting economics
Insulin, Long-Acting therapeutic use
Obesity complications
Peptides economics
Peptides therapeutic use
Venoms economics
Venoms therapeutic use
Subjects
Details
- Language :
- Spanish; Castilian
- ISSN :
- 1579-2021
- Volume :
- 58
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion
- Publication Type :
- Academic Journal
- Accession number :
- 21719364
- Full Text :
- https://doi.org/10.1016/j.endonu.2011.04.005